Short Interest in Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Rises By 196.0%

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 115,865 shares, an increase of 196.0% from the March 15th total of 39,143 shares. Based on an average daily volume of 321,290 shares, the short-interest ratio is currently 0.4 days. Currently, 8.3% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Shuttle Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in SHPH. Connective Capital Management LLC acquired a new position in Shuttle Pharmaceuticals in the 3rd quarter valued at approximately $357,000. Ikarian Capital LLC acquired a new position in Shuttle Pharmaceuticals in the 4th quarter valued at approximately $124,000. Boothbay Fund Management LLC acquired a new position in Shuttle Pharmaceuticals in the 4th quarter valued at approximately $37,000. Finally, Geode Capital Management LLC acquired a new position in Shuttle Pharmaceuticals in the 4th quarter valued at approximately $26,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Price Performance

Shuttle Pharmaceuticals stock traded down $0.03 during trading hours on Friday, hitting $0.70. The company had a trading volume of 83,212 shares, compared to its average volume of 229,380. The firm has a market capitalization of $1.12 million, a P/E ratio of -0.06 and a beta of -0.53. The firm’s fifty day moving average is $1.02 and its 200-day moving average is $1.97. Shuttle Pharmaceuticals has a fifty-two week low of $0.50 and a fifty-two week high of $12.33.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.06 earnings per share for the quarter.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .